Erschienen in:
31.03.2023 | Original Paper
Verifying the reliability of septum-enhanced inferior pedicle technique for patients with high-grade breast ptosis undergoing reduction mammaplasty
verfasst von:
Mohammed Saad AboShaban, Ahmed Abdelaziz Taalab, Fouad Mohammed Ghareeb
Erschienen in:
European Journal of Plastic Surgery
|
Ausgabe 5/2023
Einloggen, um Zugang zu erhalten
Abstract
Background
In high-grade breast ptosis, parenchyma drops inferiorly and Würinger septum descends within lower ptotic tissue. In this study, we present our technical approach to incorporate the horizontal septum with inferior pedicle for cases with high-grade breast ptosis undergoing reduction mammoplasty.
Methods
The study included 123 women (246 breasts) who presented with high-grade breast ptosis and underwent breast reduction using septum-enhanced inferior pedicle technique. The patients were divided into two groups: (1) Group I consisted of 68 patients (136 breasts) in which the preoperative SN-N distance less than 40 cm. (2) Group II consisted of 55 patients (110 breasts) in which the SN-N distance more than 40 cm.
Results
The total weight of resection per side ranged from 850 to 1500 (mean; 1250) g in group I, and 1350 to 2100 (mean; 1700) g in group II. The mean distance of the suprasternal-notch (SN-N) and the nipple-inframammary line distance were compared in each group before and after 24 months of the surgical technique, showing that a highly significant statistical difference (p values > .001) indicates superior repositioning of migrated parenchymatous tissues to the breast footprint with correction of ptosis. The complications were compared in both groups showing that a non-significant difference indicates that technique is safe and reliable with SN-N distance more than 40 cm.
Conclusions
The septum-enhanced inferior pedicle technique is safe with reliable results and minimal complications in patients with high-grade breast ptosis and gigantomastia even with a nipple to supra-sternal notch distance more than 40 cm.
Level of evidence: Level III, therapeutic study.